Name | DG172 dihydrochloride |
---|---|
Synonyms |
(2Z)-2-(2-Bromophenyl)-3-[4-(4-methyl-1-piperazinyl)phenyl]acrylonitrile dihydrochloride
Benzeneacetonitrile, 2-bromo-α-[[4-(4-methyl-1-piperazinyl)phenyl]methylene]-, (αZ)-, hydrochloride (1:2) DG172 (dihydrochloride) |
Description | DG172 dihydrochloride is a selective PPARβ/δ antagonist, with an IC50 of 27 nM. |
---|---|
Related Catalog | |
Target |
PPARβ/δ:27 nM (IC50) |
In Vitro | DG172 dihydrochloride is a selective PPARβ/δ antagonist, with an IC50 of 27 nM. DG172 enhances transcriptional corepressor recruitment, and down-regulates transcription of the PPARβ/δ target gene Angptl4 in mouse myoblasts (IC50, 9.5 nM)[1]. DG172 (1 µM) promotes the differentiation of dendritic cells (DCs) from GM-CSF-induced mouse bone marrow cells (BMCs) and reduces Ly6b+/Gr1+ granulocytic cells. DG172 has effects on the transcriptome of GM-CSF differentiated BMCs from WT and Ppard null mice, and acts at a specific stage of GM-CSF-induced differentiation[2]. DG172 (0.1, 1.0 µM) dose-dependently promotes proliferation of TM4 cells. DG172 reduces expression of claudin-11 in TM4 cells[3]. |
Cell Assay | The xCELLigence system is used for determining the changes in real time cell proliferation in response to activation of PPARD with an agonist (GW0742) or an inverse agonist (DG172) or the effect of inhibiting ERK signaling in TM4 cells[3]. |
References |
Molecular Formula | C20H22BrCl2N3 |
---|---|
Molecular Weight | 455.219 |
Exact Mass | 453.037415 |
Storage condition | 2-8℃ |